We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Phase I Study to Investigate the Alcohol Interaction of DA8159 (DA8159_DIA_I)

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: November 16, 2010
Last Update Posted: November 16, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Dong-A Pharmaceutical Co., Ltd.
Information provided by:
Asan Medical Center
This study is designed to to investigate the effects of alcohol on the pharmacokinetics of Udenafil tablet in healthy male volunteers

Condition Intervention Phase
Healthy Volunteers Erectile Dysfunction Drug: Udenafil Dietary Supplement: Alcohol Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: A Randomized, Open, Crossover Clinical Study to Investigate the Effects of Alcohol on the Pharmacokinetics of Udenafil Tablet in Healthy Male Volunteers

Further study details as provided by Asan Medical Center:

Primary Outcome Measures:
  • Pharmacokinetics (AUC and Cmax) [ Time Frame: 48 Hours ]

Enrollment: 24
Study Start Date: June 2006
Primary Completion Date: February 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Udenafil
Udenafil 200mg
Drug: Udenafil
200mg Single Oral Dose of
Active Comparator: Udenafil + Alcohol
Udenafil 200mg + Alcohol
Drug: Udenafil
200mg Single Oral Dose of
Dietary Supplement: Alcohol
Alcohol 39g / 240ml


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   19 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Adult males aged 19 to 55 years at screening.
  • Subjects with body weight ≥ 55 kg and within ±20% of the ideal body weight : Ideal body weight = (height [cm] - 100)x0.9.
  • Subjects who have received and understood completely the information regarding the current study and given written informed consents to voluntarily participate in the study and followed all instructions specified in the protocol.

Exclusion Criteria:

  • Subjects with the test results of QTc > 430 ms or non-sinus cardiac rhythm by ECG analysis.
  • Subjects with hypotension or hypertension.
  • Subjects who have drunken habitually (exceeding 21 units/week, 1 unit = 10 g of pure alcohol) or who are unable to abstain from drinking during the study period from 2 days prior to the first administration of investigational product and during this study.
  • Subjects deemed ineligible by investigator based on other reasons, including abnormal laboratory values or diseases.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01241032

Korea, Republic of
Asan Medical Center
Seoul, Korea, Republic of
Sponsors and Collaborators
Asan Medical Center
Dong-A Pharmaceutical Co., Ltd.
Principal Investigator: Kyun-Seop Bae, M.D., Ph.D. Asan Medical Center
  More Information

Additional Information:
Responsible Party: Clinical Development Team1, Dong-A Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier: NCT01241032     History of Changes
Other Study ID Numbers: 2006-0086
First Submitted: November 15, 2010
First Posted: November 16, 2010
Last Update Posted: November 16, 2010
Last Verified: November 2010

Keywords provided by Asan Medical Center:

Additional relevant MeSH terms:
Erectile Dysfunction
Sexual Dysfunction, Physiological
Genital Diseases, Male
Sexual Dysfunctions, Psychological
Mental Disorders
Anti-Infective Agents, Local
Anti-Infective Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action